Kidney transplanted patients still have significantly higher mortality compared with the general population. The innate immune system may play an important role during periods, with suppression of the adaptive immune system. In the present study, two soluble pattern recognition molecules of the innate immune system were investigated, collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). Potential associations of their pretransplant levels and long-term graft and recipient survival were examined. The levels of CL-L1 and CL-K1 were measured at the time of transplantation in 382 patients (≥17 years) transplanted in 2000-2001. The cohort was subsequently followed until December 31, 2014. Data on patient and graft survival were obtained from the Norwegian Renal Registry. Both high CL-L1 (≥376 ng/mL) and high CL-K1 (≥304 ng/mL) levels were significantly associated with overall mortality in multivariate Cox analyses with hazard ration (HR) 1.50, 95% confidence interval (CI) 1.09-2.07, p = 0.013 and HR 1.43, 95% CI 1.02-1.99, p = 0.038, respectively. Moreover, high CL-K1 levels were significantly associated with cardiovascular mortality. No association between measured biomarkers and death-censored graft loss was found. Finally, there was a significant correlation between these two collectins, r = 0.83 (95% CI 0.80-0.86). In conclusion, CL-L1 and CL-K1 were significantly associated with mortality in kidney transplant recipients.
Kidney transplanted patients still have significantly higher mortality compared with the general population. The innate immune system may play an important role during periods, with suppression of the adaptive immune system. In the present study, two soluble pattern recognition molecules of the innate immune system were investigated, collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1). Potential associations of their pretransplant levels and long-term graft and recipient survival were examined. The levels of CL-L1 and CL-K1 were measured at the time of transplantation in 382 patients (≥17 years) transplanted in [2000] [2001] . The cohort was subsequently followed until December 31, 2014. Data on patient and graft survival were obtained from the Norwegian Renal Registry. Both high CL-L1 (≥376 ng/mL) and high CL-K1 (≥304 ng/mL) levels were significantly associated with overall mortality in multivariate Cox analyses with hazard ration (HR) 1.50, 95% confidence interval (CI) 1.09-2.07, p = 0.013 and HR 1.43, 95% CI 1.02-1.99, p = 0.038, respectively. Moreover, high CL-K1 levels were significantly associated with cardiovascular mortality. No association between measured biomarkers and death-censored graft loss was found. Finally, there was a significant correlation between these two collectins, r = 0.83 (95% CI 0.80-0.86). In conclusion, CL-L1 and CL-K1 were significantly associated with mortality in kidney transplant recipients.
Introduction
Kidney transplantation is the treatment of choice in patients with end-stage renal disease. It is associated with improved survival and reduced morbidity (1) . The use of immunosuppressive drugs increases the risk of both infections and malignancy. The role of specific parts of the immune system may be relevant for both infections and malignancies in transplant recipients.
The complement system is an important component of the innate immune system and participates in a number of processes, eg defense against infection, homeostatic processes removing altered/dead self-tissue, ischemiareperfusion injury and coagulation.
The complement system can be activated by three pathways: the classical, the alternative and the lectin pathways, as described in detail previously (2, 3 and MBL-associated proteins [MAps]), which provide for either activation or inhibition of the lectin pathway. Two additional soluble proteins, collectin liver 1 (CL-L1, also known as collectin-10) and collectin kidney 1 (CL-K1, also known as collectin-11), have been identified as novel members of the collectin family (4, 5) . Both CL-L1 and CL-K1 can bind to carbohydrate ligands and DNA on microbial surfaces or on the membrane of damaged cells, interact with MASPs and activate the lectin pathway of the complement system in a manner similar to that of MBL and ficolins (6) (7) (8) . In vitro studies showed that CL-K1 has higher binding ability to DNA and mediates higher C4d deposition than MBL. CL-L1 and CL-K1 in the circulation form heteromeric complexes (CL-LK) with each other, increasing their complement activating potential (6) . We thus have a number of recognition molecules with similar functionality but with different specificities for microorganisms and other structures.
Because CL-L1 and CL-K1 were only recently discovered, the clinical influence of these molecules is largely unknown. Studies have shown that a high activity of the lectin pathway, expressed as high levels of ficolin-3, MBL or MASPs at the time of transplantation, may be associated with poor graft and patient survival after kidney transplantation (9-12). Recently, it was shown that CL-K1 was associated with complement-mediated epithelial injury in a mouse model of acute kidney injury. Renal ischemia reperfusion injury led to increased CL-K1 expression and disorganized patterns of fucosylated glycoconjugates at the proximal tubules, which mediated CL-K1 binding and MASP-2-dependent complement activation (13) .
The aim of the present study is to investigate the association of CL-L1 and CL-K1 levels at the time of transplantation and long-term graft and recipient survival after kidney transplantation and to assess the possible correlation between levels of CL-L1 and CL-K1 in the study population as further evidence of heteromeric CL-LK complexes.
Materials and Methods

Study population
In the present study we investigated a cohort of 402 adult kidney recipients, transplanted in 2000 and 2001 at Oslo University Hospital Rikshospitalet. Only patients ≥17 years were included in the study. Blood samples at the time of transplantation were available for 382 patients, who all signed an informed consent about use of medical information and biomaterials for scientific purposes. Prophylaxis with trimethoprimsulfamethoxazole against Pneumocystis jirovecii was used as a routine. No patients received prophylaxis against cytomegalovirus (CMV) but were treated with valganciclovir at first positive CMV antigen test. The cohort has previously been described (9) , but in the present study the follow-up period was extended until December 31, 2014. Data on patient survival were obtained from the Norwegian Renal Registry. The study was approved by the Regional Ethics Committee (approval number 2009/147-1 REK Sor-Ost D).
Immunosuppressive treatment
All patients received steroids, except for 10 patients who participated in the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial and followed a steroid-free protocol (14) . Immunosuppressive regimen was routinely based on a calcineurin inhibitor. Only in 5 patients with hemolytic uremic syndrome was calcineurin inhibitor replaced by sirolimus. Calcineurin inhibitors were combined either with mycophenolate mofetil (MMF) or with induction therapy. Induction therapy was given to 161 (42%) patients with basiliximab (Simulect â , Novartis, Stein, Switzerland), and to 1 patient with anti-thymocyte globulin (ATG). The remaining 220 (58%) received MMF in combination with calcineurin inhibitor and steroids. Only 13 patients received quadruple immunosuppression with basiliximab, calcineurin inhibitors, MMF and steroids. Two patients who were previously lung and heart transplanted received azathioprine initially in combination with cyclosporine and steroids.
Immunological assays
CL-L1:
The assay was performed as previously described (8) . Microtiter plates were coated with 0.5 lg of monoclonal anti-CL-L1 antibody in 100-lL phosphate-buffered saline (PBS) with isotonic NaCl concentration.
Residual binding sites were blocked with 1 mg human serum albumin (HSA) per mL Tris-buffered saline (TBS; 10 mM Tris, 145 mM NaCl, pH 7.4). After wash, citrate plasma samples and four citrate plasma quality controls were diluted 40-fold in CL-L1 binding buffer (TBS containing 0.05% Tween 20, 10 mM ethylenediaminetetraacetic acid [EDTA], 100 lg heat-aggregated human IgG and 10 lg normal rabbit IgG per mL) and added to the wells. A standard curve was constructed from a citrate plasma pool (with a known amount of CL-L1) diluted 10-fold and subsequently 7 times twofold in CL-L1 binding buffer. After overnight incubation at 4°C and wash, the wells were incubated with 0.1 lg polyclonal biotin-conjugated rabbit anti-CL-L1 antibody in 100 lL TBS/ Tween/10 mM EDTA. Europium-labeled streptavidin (Perkin Elmer, Waltham, MA) was diluted 1000-fold and added to the wells after incubation for 2 h. Finally, enhancement solution was added, and the signal was read by time-resolved fluorometry. Interassay reproducibility was assessed by determining CL-L1 in four different control citrate plasma samples on each plate (coefficient of variation: 7.4% for 2355 ng/ mL, 6.4% for 1699 ng/mL, 8.0% for 921 ng/mL, 9.1% for 638 ng/mL). Regarding the concentrations given for CL-L1 for the present report, we determined the concentration of CL-L1 in the standard serum using a new and better characterized preparation of recombinant CL-L1, resulting in levels approximately three times lower than given in our original report (8) .
CL-K1:
The assay was performed as previously described (15) .
Microtiter plates were incubated with 0.5 lg of monoclonal anti-CL-K1 antibody , and residual binding sites were blocked with 1 mg HSA per mL TBS. After washing, citrate plasma samples and four citrate plasma quality controls were diluted 50-fold in CL-K1 binding buffer (TBS containing 0.05% Tween 20, 5 mM EDTA, 100 lg heat-aggregated human IgG and 0.1% bovine serum) and added to the wells. A standard curve was constructed using a citrate plasma pool with a known amount of CL-K1, which was run in 7 times twofold dilutions in CL-K1 binding buffer. After overnight incubation at 4°C and wash, the wells were incubated with 0.5 lg/mL biotin-conjugated monoclonal anti-CL-K1 antibody (14-29) in 100 lL TBS/Tween/5 mM EDTA. Europium-labeled streptavidin was diluted 1000-fold and added to the wells after incubation for 2 h. Finally, enhancement solution was added, and the signal was read by time-resolved fluorometry. Interassay reproducibility was assessed by determining CL-K1 in three different control citrate plasma samples on each plate (coefficient of variation: 8% for 231 ng/mL, 8% for 147 ng/mL, 7% for 71 ng/mL).
Statistical analyses
The levels of tested biomarker were divided into quartiles because the functional relationship between biomarkers and risk of patient death is unknown. Survival curves for third and fourth quartiles diverged significantly from survival curves for first and second quartiles, thus cut-off points were made at median concentration values of ≥376 ng/mL for CL-L1 and ≥304 ng/mL for CL-K1. Dichotomized variables representing high versus low CL-L1 and high versus low CL-K1 were used in the following regression analyses. A number of relevant variables known to be associated with decreased survival were tested as important predictors and potential confounders in univariable Cox models: CMV infection during the first 100 days after transplantation (as a time-dependent variable), recipient age per year, recipient sex, donor age per year, coronary heart disease, hypertensive nephropathy and diabetic nephropathy at the time of transplantation. Several variables that potentially improve long-term outcomes after transplantation were tested as well: living donor, preemptive transplantation (previously not taken in renal replacement therapy) and induction with basiliximab. Because 18% of the study population were preemptively transplanted, dialysis time could not be included in the Cox analyses of the whole study population. However, effects of biomarkers adjusted for time in dialysis per month were assessed in a subcohort of patients who underwent dialysis before the current transplantation. Only variables with p < 0.2 in the univariable analyses were included in multivariable Cox regression analyses. To avoid overfitting, ie spurious effects due to too few events per explanatory variable, fewer variables were included in the multivariable Cox models for mortality resulting from infections and cardiovascular causes. For each Cox model, the proportional hazard assumption was checked with a test based on Schoenfeld residuals.
To compare the baseline data, Pearson chi-squared test was used to compare categorical variables, and median regression was used to compare medians. To determine discriminatory accuracy, we estimated the area under the curve (AUC) with 95% confidence intervals (CIs) and plotted the receiver operating characteristic (ROC) curves for CL-L1 and CL-K1 (with mortality as outcome).
The association between CL-L1 and CL-K1 concentrations was estimated by the Pearson correlation coefficient.
The statistical software SPSS (SPSS 21, Inc., Chicago, IL) and Stata 14 (StataCorp LP, College Station, TX) were used to perform the statistical analyses.
Results
General outcomes
At baseline, 382 patients were included. Median observation time was 13.3 (range 0.1-15) years. During this period, 157 (41%) patients died. Median time to death was 6.8 (range 0.1-14) years. Causes of death were cardiovascular events in 68 patients. Thirty-four patients died as a result of infection and 28 owing to malignant diseases. The residual 27 deaths occurred because of other causes. The median levels of CL-L1 and of CL-K1 were 376 ng/mL and 305 ng/mL, respectively. We observed some differences in the baseline characteristics between groups with high versus low CL-L1 and high versus low CL-K1 (Table 1) . A majority of preemptively transplanted patients was in the low CL-L1 group (p = 0.03). Median CL-L1 values were 366 ng/mL in preemptively transplanted and 386 ng/mL in non-preemptively transplanted patients (p = 0.11). No difference in median levels of CL-K1 across the same groups was found (p = 0.49). Significantly more patients with diabetic nephropathy were in the high CL-K1 group. Median levels of CL-K1 in patients with and without diabetic nephropathy were 356 and 295 ng/mL, respectively (p < 0.001). No statistically significant difference in median CL-K1 levels in recipients younger and older than the median age of 51.7 years was found (p = 0.075). No differences in the frequency of CMV infection during the first 100 days after transplantation were found across the groups high/low CL-L1 analysis of specific death causes, high CL-L1 was associated with mortality due to infectious diseases but lost significance when adjusted to other risk factors (data not shown).
CL-K1:
High CL-K1 (≥305 ng/mL) was significantly associated with increased mortality in univariable analysis (Figure 2 ). The statistically significant association remained in the multivariable Cox analysis, with HR 1.43, 95% CI 1.02-1.99 and p = 0.038. Other significant risk factors for overall mortality were recipient age (per year) and diabetic nephropathy (Table 3) . In multivariable Cox analysis for overall mortality in the subcohort of 303 patients who underwent dialysis before the current transplantation, CL-K1 remained statistically significant, with HR 1.53, 95% CI 1.07-2.20 and p = 0.02, adjusted for dialysis time per month (HR 1.02, 95% CI 1.00-1.03, p = 0.06), recipient age and diabetic nephropathy. In the multivariable Cox analysis of mortality due to cardiovascular causes, high CL-K1 showed a significant association with mortality, with HR 1.97, 95% CI 1.18-3.29 and p = 0.009 (Table 4 ). Other significant risk factors for cardiovascular mortality were recipient age (per year) and coronary heart disease at the time of transplantation.
Acute rejections and graft loss
We found no difference in the frequency of acute rejection episodes between groups with high versus low CL-L1 and high versus low CL-K1. Neither CL-L1 nor CL-K1 was a significant risk factor for death-censored graft loss in univariable Cox analyses.
Correlation between the collectins
We found a strong and highly statistically significant correlation between CL-L1 and CL-K1 concentrations in serum (r = 0.83 [95% CI 0.80-0.86], p < 0.001; Figure 3 ). Because of this strong correlation, which led to estimation problems from collinearity, we could not explore the simultaneous association of CL-L1 and CL-K1 on mortality in a multivariable Cox regression model.
Discrimination
The AUC with mortality as outcome for CL-L1 was 0.58 (95% CI 0.52-0.64), and the AUC for CL-K1 was 0.60 (95% CI 0.54-0.66). The corresponding ROC curves are provided in the supplemental materials ( Figures S1 and  S2 ).
Discussion
In the present study we investigated the association of the most recently discovered pattern recognition molecules of the lectin complement pathway, CL-K1 and CL-L1, with long-term outcomes after kidney transplantation. Biomarker concentrations of median levels or higher at the time of transplantation were found to be significantly associated with increased long-term overall mortality in kidney graft recipients.
CL-L1 was initially described as a cytoplasmatic protein with highest expression in hepatocytes (5) . In succeeding studies both CL-K1 and CL-L1 were detected in circulation (6, 8) . The highest CL-K1 mRNA expressions were found in adrenal glands, liver and kidney (16, 17) . In kidneys the staining of CL-K1 was predominantly localized to proximal and distal tubules. In plasma the majority of CL-L1 and CL-K1 is found in heteromeric subunits composed of one CL-L1 and two CL-K1 polypeptide chains; this molecule is also named CL-LK (6) . In line with the discovered existence of CL-LK complex, we observed a highly significant correlation between CL-L1 and CL-K1 levels in the present study, in accordance with BayarriOlmos et al and Troldborg et al (18, 19) . Intriguingly, the formation of the CL-LK complex is important for interaction with MASPs, particularly with MASP-2. The same study found that the interaction between CL-LK and MASPs mediates the complement activation and leads to initiation of the complement cascade as shown, for example, by C4b deposition in vitro (6).
The impact of CL-L1 and CL-K1 levels on long-term survival discovered in the present study is a novel finding, and the biological mechanism of such influence is largely unknown. The complement system participates in numerous processes in the body. Storm et al propose to use CL-L1 as a screening biomarker for colorectal cancer (20) . The elevated levels of CL-L1 were observed both in the early phase of acute liver failure and in cirrhosis (21). Axelgaard et al followed the CL-L1 levels in 10 healthy individuals over a 1-year period; in 12 infants at 6, 9 and 12 months; and in 6 patients after operation for colorectal cancer. The research group concluded that CL-L1 does not behave as a classical acute-phase protein (8). Takahashi intravascular coagulation (22) . Furthermore, no statistical differences in median CL-K1 levels across four age groups of ages 20 to 100 years or in patients with renal diseases and diabetes mellitus were found. On the other hand, the patients with vascular diseases had higher incidence of elevated CL-K1. In the present study the median CL-K1 concentration of 304 ng/mL is comparable with median levels among healthy Americans, 265 ng/ mL (22) ; healthy Japanese, 340 ng/mL (23); and healthy Danes, 284 ng/mL (15) . In the present study a complete cohort of patients transplanted in 2000-2001 was investigated. There were some differences in the baseline data. A majority of patients who were preemptively transplanted were in the low CL-L1 group, and a greater number of patients with living donor were in the low CL-K1 group. We found, as well, greater prevalence of diabetic nephropathy in the high CL-K1 group. Furthermore, we found higher CL-K1 levels in patients with diabetic nephropathy, but no interaction between CL-K1 and diabetic nephropathy in survival analyses. Assumedly, these differences in baseline data may explain why some covariables turned out to be nonsignificant in multivariable analyses. However, the effect of collectins remained stable and significant when adjusted for chosen possible confounders both in the whole cohort and in the subcohort of patients who underwent dialysis before transplantation. Furthermore, we found no variation in the median collectin levels in patients younger and older than the median age of 51.7 years. Thus, this may indicate that collectin levels within one individual remain relatively stable during life but probably that diabetes or chronic kidney failure could interfere with them. A future study of collectin levels before and after transplantation in the same individuals could shed more light on this topic. In the present study high CL-K1 was associated with cardiovascular mortality to the same strength as pretransplant coronary heart disease. Taking into consideration the findings of Takahashi et al, we may assume that CL-K1 is involved in coagulation processes and thrombotic events.
The strength of the present study, based on a large cohort that allowed us to draw statistical conclusions, is reasonable. The high-quality register data provided a complete follow-up of all patients over a long period of time after transplantation. However, the study is observational and can point out an association, but cannot affirm causality. Analyses of discrimination accuracy for CL-L1 and CL-K1 with mortality as the outcome showed only low discrimination ability. Another limitation of the study is that it doesn't take into account posttransplant diabetes mellitus or other events occurring after transplantation except for early CMV infection. Additional studies are therefore needed to confirm our data.
In conclusion, the main finding of the present study is that high levels of CL-L1 and CL-K1 at the time of transplantation are significantly associated with increased long-term overall mortality after kidney transplantation. CL-K1 was associated with cardiovascular mortality to the same strength as pretransplant coronary heart disease. The serum levels of these two proteins are highly correlated. The findings of the study are novel and may indicate an influence of the lectin complement pathway on long-term outcomes after kidney transplantation. However, precise mechanisms of the adverse action need to be investigated.
